Phase 3 Trial Pfizer’s BRAFTOVI® Combo Boosts Survival
Phase 3 Trial Pfizer has announced significant and positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER clinical trial. This trial assessed the efficacy of…
Antibody Breakthrough Inhalon Biopharma Unveils First Inhaled for RSV in Human Trials
Inhalon Biopharma a clinical-stage biotechnology company focused on developing innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the advancement of its inhaled antibody platform. The…
Median Technologies eyonis™ LCS Hits Primary Endpoint in RELIVE Trial, Final Step for Regulatory Submission
Median Technologies has announced a significant milestone in its mission to revolutionize lung cancer screening. The company’s proprietary artificial intelligence (AI) and machine learning (ML)-based software, eyonis™ Lung Cancer Screening…
Vertex Secures CASGEVY® Reimbursement Agreement for Sickle Cell Disease Treatment in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy,…
IMCAS 2025: Galderma Phase IIIb Data Show Rapid, Long-Lasting Benefits of Relfydess™
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient…
Sumitomo Pharma Reports TWYMEEG® Q4 2024 Sales and Full-Year Forecast in Japan
Poxel SA and Sumitomo Pharma: A Closer Look at TWYMEEG®’s Sales Performance and Strategic Growth Initiatives In the rapidly evolving landscape of metabolic disease treatments, Poxel SA (Euronext: POXEL –…
Ethris Unveils Positive Phase 1 Data for mRNA Candidate ETH47 in Asthma
Ethris Reports Promising Phase 1 Data for mRNA Candidate ETH47 in Asthma Ethris GmbH, a pioneering biotechnology company specializing in next-generation RNA therapeutics and vaccines, has unveiled encouraging topline data…
Owkin Doses First Patient in Phase I Trial of OKN4395 for Solid Tumors
Owkin Announces First Patient Dosed in Phase I Trial of OKN4395 for Solid Tumors Owkin, a leader in AI-driven biotech, has reached a significant milestone in its innovative journey with…
Galderma Leads in Aesthetic Injectables & Weight Loss Research
Galderma Leads in Aesthetic Injectables & Weight Loss Research New research reveals that loose or sagging skin on the face and neck is most commonly observed after medication-driven weight loss,…
Quanta System Celebrates 40 Years & New IMCAS 2025 Partnership
40 Years of Excellence in Laser Technology Quanta System proudly celebrates a major milestone in 2025-40 years of pioneering innovation in laser technology. Since its founding in 1985, it has…
KORU Medical Systems Partners on Phase III Clinical Trial for Innovative Nephrology Drug Indication
KORU Medical Systems Partners on Phase III Trial for Rare Renal Disorder Treatment, Expanding Its Reach in Subcutaneous Infusion Solutions KORU Medical Systems (NASDAQ: KRMD), a leading innovator in large-volume…
Enveric Biosciences Granted Patent Allowance for Lead Drug Candidate EB-003 by USPTO
Enveric Biosciences Secures Patent Protection for Breakthrough Neuroplastogen EB-003 In a significant milestone for its innovative drug development pipeline, Enveric Biosciences (NASDAQ: ENVB) has announced the receipt of a Notice…